Seeking Alpha

OPKO Health, Inc. (OPK)

  • Tue, May 5, 11:26 AM
    • OPKO Health (OPK -1.9%) acquires Waterford, Ireland-based EirGen Pharma, a developer of specialty high potency pharmaceuticals, such as those used for cancer chemotherapy. Financial terms are undisclosed.
  • Thu, Feb. 5, 3:23 PM
    • The resignation of prominent healthcare investor/entrepreneur Dr. Phillip Frost, M.D., from Teva Pharmaceutical Industries' (TEVA +1.8%) Board of Directors prompts aggressive buying from speculators who think a potential deal is afoot with Opko Health (OPK +4.6%). Teva is up on 50% higher volume while Opko's turnover is 3x average.
  • Dec. 16, 2013, 9:22 AM
    • OPKO Health (OPK) acquires Laboratorio Arama de Uruguay. Terms were undisclosed, with closing expected in Jan.
    • CEO Phillip Frost: "This acquisition will allow OPKO to establish a footprint in Uruguay and facilitate future sales and commercial expansion into neighboring Argentina. In the near term, Arama provides another platform for the commercialization of our 4Kscore."
    • OPK shares +4.9% AH
    | 1 Comment
  • Aug. 29, 2013, 4:09 PM
    • Opko Health (OPK -1%) says it's completed its acquisition of Prolor Biotech (PBTH).
    • Under the terms of the deal, each PBTH stockholder will receive 0.9951 shares of OPK.
    • The acquisition provides OPK with four significant products in Phase III clinical development, as well as a pipeline of important therapeutic and unique diagnostic products in various stages of development.
  • Apr. 24, 2013, 9:08 AM
    Prolor Biotech (PBTH), will be acquired by OPKO Health (OPK) in an all-stock deal worth $480M. PBTH shareholders will get 0.9551 shares of OPK for every share of PBTH they own, equating to $7 per share as of Tuesday's closing prices. PBTH +10.65% premarket. (Previously: strategic alternative evaluation boosts Prolor)
  • Dec. 27, 2012, 1:04 PM
    Drugmaker and diagnostics firm Opko Health (OPK +0.5%) acquires Brazilian pharmaceutical company Silcon Comercio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos Ltda. The acquisition represents an important strategic move for OPK's diagnostic business. It permits the commercialization of its prostate cancer test in the region while the company obtains local approval to market its point of care microfluidics disposable test cassettes.
    | Comment!
  • Oct. 13, 2011, 8:58 AM
    Opko Health (OPK) announces the acquisition of Claros Diagnostics for an undisclosed amount in a move its CEO says will provide "near-term commercialization possibilities" from the use of the firm's microfluidics technology.
    | Comment!
Visit Seeking Alpha's
OPK vs. ETF Alternatives
Company Description
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.